Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Assets (2024 - 2025)

Prelude Therapeutics' Non-Current Assets history spans 2 years, with the latest figure at $35.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 10.09% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $148.9 million, down 9.05%, while the annual FY2025 figure was $35.6 million, 10.09% down from the prior year.
  • Non-Current Assets for Q4 2025 was $35.6 million at Prelude Therapeutics, down from $36.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $41.7 million in Q1 2024 and bottomed at $35.6 million in Q4 2025.